Fampridine for Symptomatic Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double‐Blinded, Placebo‐Controlled Crossover Study
Peter Nørregaard Hansen, Lars Markvardsen, Hatice Tankisi, Henning Andersen, Thomas Krøigård, Søren Sindrup · 2026
Read Fampridine for Symptomatic Treatment in Chronic Inflammatory Demyelinating Polyneuropathy: A Randomized, Double‐Blinded, Placebo‐Controlled Crossover Study by Peter Nørregaard Hansen, Lars Markvardsen, Hatice Tankisi, Henning Andersen, Thomas Krøigård, Søren Sindrup (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13612250.txt.
Description
Peter Hansen, Lars Markvardsen, Hatice Tankisi, Henning Andersen, Thomas Krøigård, and Søren Sindrup ran this clinical trial, published in 2026. It tested fampridine, a drug that blocks potassium channels, in people with a nerve disease called CIDP. The disease weakens nerves, and many patients stay disabled despite standard immune treatment.
Twenty-eight patients took the drug and a placebo in turn, four weeks each, without knowing which was which. The two main tests, a stepping test and a peg test for hand skill, showed no gain on the drug. Grip strength and one daily-living score actually got worse on fampridine. One nerve signal measure improved, but the rest did not. No serious side effects appeared. The authors conclude the drug does not help these patients, though the channel idea stays open.
Catalog record
| CREATOR | Peter Nørregaard Hansen, Lars Markvardsen, Hatice Tankisi, Henning Andersen, Thomas Krøigård, Søren Sindrup |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 47 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |